ALT - Altimmune Inc

ALT - Altimmune Inc

https://altimmune.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Shareholders that lost money on Altimmune, Inc. ( ALT ) Urged to Join Class Action - Contact The Gross Law Firm to Learn More - Altimmune ( NASDAQ:ALT )

Benzinga • 0 minutes ago • score: 0.06

NEW YORK, Sept. 15, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. ALT. Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer - Altimmune ( NASDAQ:ALT )

Benzinga • 4 hours, 27 minutes ago • score: 0.44

GAITHERSBURG, Md., Sept. 15, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ALT, a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M.

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

GlobeNewswire • 4 hours, 27 minutes ago • score: 0.25

GAITHERSBURG, Md., Sept. 15, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ( Nasdaq: ALT ) , a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M.

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm - Altimmune ( NASDAQ:ALT ) , SelectQuote ( NYSE:SLQT )

Benzinga • 4 hours, 43 minutes ago • score: 0.04

NEW YORK, Sept. 15, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Altimmune, Inc. ALT and SelectQuote, Inc.

ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT - Altimmune ( NASDAQ:ALT )

Benzinga • 2 days, 17 hours ago • score: 0.14

NEW YORK, Sept. 12, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. ALT between August 10, 2023 and June 25, 2025 ( the "Class Period" ) , of the important October 6, 2025 lead plaintiff deadline.

Class Action Filed Against Altimmune, Inc. - Investors with Losses Encouraged to Contact Johnson Fistel - Altimmune ( NASDAQ:ALT )

Benzinga • 3 days, 1 hour ago • score: 0.06

SAN DIEGO, Sept. 12, 2025 ( GLOBE NEWSWIRE ) -- Shareholder rights law firm Johnson Fistel, PLLP, announces that a class action lawsuit has been filed on behalf of investors who purchased securities of Altimmune, Inc. ( "Altimmune" ) ALT between August 10, 2023 and June 25, 2025, inclusive ( the ...

Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT - Altimmune ( NASDAQ:ALT )

Benzinga • 3 days, 17 hours ago • score: 0.18

Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options

Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT - Altimmune ( NASDAQ:ALT )

Benzinga • 3 days, 19 hours ago • score: -0.03

NEW YORK, Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ( "Altimmune" or the "Company" ) ALT of a class action securities lawsuit.

ROSEN, A LONGSTANDING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT - Altimmune ( NASDAQ:ALT )

Benzinga • 5 days, 14 hours ago • score: 0.14

NEW YORK, Sept. 09, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. ALT between August 10, 2023 and June 25, 2025 ( the "Class Period" ) , of the important October 6, 2025 lead plaintiff deadline.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company is headquartered in Gaithersburg, Maryland.

52W High

$11.16

52W Low

$2.90

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.18

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-4.20

EV/Revenue (<3 favorable)

8317.82

P/S (TTM) (<3 favorable)

16680.63

P/B (<3 favorable)

2.07

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

0.78%

Institutions (25–75% balanced)

43.31%

Shares Outstanding

88,257,000

Float

87,578,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

2017-01-20

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

20,000

Gross Profit (TTM)

-72,627,000

EPS (TTM)

-1.18

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-4584.40%

ROE (TTM) (>15% strong)

-0.56%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0480

Previous

-0.0461

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025